Study Detail: Genentech Anti-Factor D
Trial Description Summary : First human trials of new human monoclonal antibody given one time intra-vitrally for Geographic Atrophy (Dry macular degeneration)
Basic Trial Information
Phase: 1a
Disease: Geographic Atrophy (dry macular degeneration)
Sponsor: Genentech
Protocol Number: CFD4711g
Status: Enrolling
Study Duration: 6 months plus 2 week screening period
Eligibility Criteria
Inclusion Criteria
GA at least 0.75 disc areas in the absence of CNV
BCVA 20/125-20/400 inclusive
Exclusion Criteria
Wet AMD in either eye
Diabetic retinopathy
Previous ITV drug delivery
Use of Visudyne, external-beam radiation therapy or TTT in EITHER eye
Any prior treatment (except vitamins/mineral) for wet or dry AMD in either eye
The above inclusion/exclusion criteria is not complete and the study coordinator will do a complete screening.
Study Title : A phase 1a, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics and immunogenicity of intravitreal injections of FCFD4514S in patients with geographic atrophy
Trial Contact Information
Site: Beachwood
Study Coordinator: Dianne H 216/831-5704 x 253


